MARKET

CORT

CORT

Corcept Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.44
+1.66
+6.98%
After Hours: 26.50 +1.06 +4.17% 19:09 07/01 EDT
OPEN
23.94
PREV CLOSE
23.78
HIGH
25.60
LOW
23.94
VOLUME
894.27K
TURNOVER
0
52 WEEK HIGH
25.68
52 WEEK LOW
15.83
MARKET CAP
2.70B
P/E (TTM)
27.86
1D
5D
1M
3M
1Y
5Y
Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer
Corcept Therapeutics (NASDAQ:CORT) has <a href=...
Seekingalpha · 3d ago
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel aloneMENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWI...
GlobeNewswire · 3d ago
Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling
Biotech stock Corcept is flirting with a buy point after the U.S. Supreme Court overturned constitutional protections for abortion.
Investor's Business Daily · 4d ago
Dow Jones Dips; Donald Trump SPAC Dives On This Move; Apple Stock Whipsaws Amid Wall Street Call
The Dow Jones fell. The Donald Trump SPAC took a dive amid legal woes. Apple stock treaded water after an analyst call.
Investor's Business Daily · 5d ago
After A 20% Rally This Month, Here's Why This Biotech Is Worth Considering
Biotech stocks like Corcept Therapeutics are worth considering for your portfolio as shares near a proper buy point amid a powerful rally.
Investor's Business Daily · 5d ago
Why a Peninsula rare disease drug company is turning toward cancer
Starting with a late-stage clinical trial in ovarian cancer, the 24-year-old company is looking to prove that controlling a hormone found in every organ can have an impact beyond its initial rare disease approval a decade ago.
American City Business Journals · 06/24 20:11
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
Small-cap drug maker Corcept Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 85 to 91. The new 91 RS Rating means Corcept stock has outperformed 90% of all other stocks over the past year. Market rese...
Investor's Business Daily · 06/23 07:00
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 06/22 14:06
More
No Data
Learn about the latest financial forecast of CORT. Analyze the recent business situations of Corcept Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
16.67%Hold
16.67%Under-perform
0.00%Sell
Analyst Price Target
The average CORT stock price target is 27.50 with a high estimate of 35.00 and a low estimate of 16.00.
High35.00
Average27.50
Low16.00
Current 25.44
EPS
Actual
Estimate
0.070.130.200.26
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 332
Institutional Holdings: 104.45M
% Owned: 98.30%
Shares Outstanding: 106.25M
TypeInstitutionsShares
Increased
69
4.00M
New
39
1.30M
Decreased
81
3.87M
Sold Out
19
585.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
James Wilson
President/Chief Executive Officer/Co-Founder/Director
Joseph Belanoff
Chief Financial Officer/Treasurer
Atabak Mokari
Corporate Executive
Sean Maduck
Chief Accounting Officer
Joseph Lyon
Chief Scientific Officer
Hazel Hunt
Other
William Guyer
Secretary
Gary Robb
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
Gillian Cannon
Independent Director
David Mahoney
Independent Director
Joshua Murray
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
No Data
No Data
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.